Fawaz Aldabbagh: research interests

Drug Discovery

Synthesis and anti-cancer activity of novel small organic heterocyclic molecules (incl. benzimidazolequinones).
Past synthetic methods used include radical cyclizations, 1,3-dipolar cycloadditions and photochemistry.
Selected heterocycles have shown high specificity towards Fanconi anemia, breast, cervical and prostate cancer.

Recent publications:

1) V. Fagan, S. Bonham, M. P. Carty and F. Aldabbagh. One-Pot Double Intramolecular Homolytic Aromatic Substitution Routes to Dialicyclic Ring Fused Imidazobenzimidazolequinones and Preliminary Analysis of Anti-Cancer Activity. Organic and Biomolecular Chemistry. 2010, 8, 3149-3156.

2) L. O'Donovan, M. P. Carty and F. Aldabbagh. RSC Prospect: "First Synthesis of N-[(Aziridinyl-2-yl)methyl]Benzimidazolequinone and Analysis of Toxicity Towards Normal and Fanconi Anemia Cells. Chemical Commun., 2008, 5592-5594.

3) M. Lynch, S. Hehir, P. Kavanagh, D. Leech, J. O'Shaughnessy, M. P. Carty, F. Aldabbagh, Synthesis by Radical Cyclization and Cytotoxicity of Highly Potent Bioreductive Alicyclic Ring Fused [1,2-a]Benzimidazolequinones. Chem. Eur. J. 2007, 13, 3010. DOI Link.

Polymer Chemistry and Materials Science

Radical polymerizations, include nitroxide mediated controlled/living polymerizations, ring-opening polymerizations and with macromonomers, use of supercritical carbon dioxide and ionic liquids.

Recent publications

1) P. O'Connor, P. B. Zetterlund and F. Aldabbagh. Effect of Monomer Loading and Pressure on Particle Formation in Nitroxide-Mediated Precipitation Polymerization in Supercritical Carbon Dioxide. Macromolecules, 2010, 43, 914-919.

2) P. B. Zetterlund, F. Aldabbagh, M. Okubo. Controlled/Living Heterogeneous Radical Polymerization in Supercritical Carbon Dioxide. Journal of Polymer Science: Part A: Polymer Chemistry 2009, 47, 3711-3728.

3) F. Aldabbagh, P. B. Zetterlund, M. Okubo. Improved Control in Nitroxide-Mediated Radical Polymerization Using Supercritical Carbon Dioxide. Macromolecules 2008, 41, 2732-2734.        

• Disclaimer
• Privacy
• Copyright
• Accessibility